1. Home
  2. INCR vs IFRX Comparison

INCR vs IFRX Comparison

Compare INCR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.85

Market Cap

50.4M

Sector

Health Care

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.92

Market Cap

60.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INCR
IFRX
Founded
1994
2007
Country
Israel
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.4M
60.6M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
INCR
IFRX
Price
$0.85
$0.92
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
52.1K
253.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$69.54
N/A
Revenue Next Year
$41.75
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.71
52 Week High
$1.77
$1.94

Technical Indicators

Market Signals
Indicator
INCR
IFRX
Relative Strength Index (RSI) 45.31 50.37
Support Level $0.76 $0.81
Resistance Level $0.98 $1.16
Average True Range (ATR) 0.05 0.05
MACD 0.00 0.01
Stochastic Oscillator 58.58 72.11

Price Performance

Historical Comparison
INCR
IFRX

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: